Replimune Group

REPL

Biotechnology · Healthcare

Price

$14.77

+0.72 (+5.12%)

Market Cap

$1.24B

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+77.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 52.2M (2022) → 92.8M (2026)

Winston Score History

The full picture

Replimune is a biotechnology company that develops cancer treatments using a special type of modified virus called an oncolytic virus. These viruses are engineered to infect and kill tumor cells while also triggering the body's immune system to fight the cancer. The company's lead product, RP1 (vusolimogene oderparepvec), targets skin cancers like melanoma, and its main customers are cancer patients and the oncologists who treat them.

Replimune makes money by advancing its drug candidates through clinical trials, with the goal of eventually selling approved medicines to hospitals and clinics. The company is based in the United States and operates primarily in early-to-mid stage drug development, meaning it currently generates little to no product revenue and funds itself through equity raises and partnerships. Its key growth driver is winning regulatory approval for RP1, which received FDA Breakthrough Therapy designation, but the main risk is that clinical trials could fail, and the company continues to burn significant cash with no guaranteed path to profitability.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+24.2% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$221M/ year

↑ Rising (+17% vs prior year)

R&D investment increasing — building for the future

Insider Activity

6.3%ownership

↓ Declining

Insider ownership declining — could be dilution or selling

Cash Runway

~8 months

$195M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Replimune Group has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-156.9%

Weak — -156.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.80

Moderate — manageable debt (0.80)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial